Cytoreductive nephrectomy in metastatic renal cell carcinoma under immunotherapy: A multicenter retrospective analysis (DGU 2026) - Oct 15, 2026 - Abstract #V38-09; Pres time: Sep 18, 2026; 10:10 AM - 10:20 AM; Location: Room 19; "Materials and This multicenter retrospective cohort study included 309 patients from six German university hospitals (November 2017–December 2024) who received first-line immunotherapy combination therapy (nivolumab/ipilimumab or IO-TKI regimen). This real-world study provides hypothesis-generating evidence for a PFS benefit of CN in selected mRCC patients receiving combination immunotherapy. Prospective validation through ongoing studies is still pending before implementation in routine clinical practice."
Metastases • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
M. Sondermann 1; CC Garcia 2; M. Jahnen 3; M. Daeuwel 4; A. Mattigk 5; B. Height 1; F. Zengerling 5; C. Humke 2; JE Gschwend 3; K. Erdmann 1; P. Zeuschner 6; C. Kalogirou 4
|